Advertisement

Topics

Fixed Chemo Combo Vyxeos Approved for High-Risk AML

08:09 EDT 3 Aug 2017 | Medscape

The fixed chemotherapy combination of daunorubicin and cytarabine, Vyxeos, has been approved for certain cases of high-risk acute myeloid leukemia.
FDA Approvals

Original Article: Fixed Chemo Combo Vyxeos Approved for High-Risk AML

NEXT ARTICLE

More From BioPortfolio on "Fixed Chemo Combo Vyxeos Approved for High-Risk AML"

Quick Search
Advertisement
 

Relevant Topics

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...